AMNet Logo

Join AMNet: An Addiction Medicine Practice-Based Research Network

AMNet is a network of office-based addiction medicine prescribers working to address the opioid epidemic and improve patient outcomes.

Your Participation Makes a Difference

AMNet is seeking addiction medicine and addiction psychiatry practices and their providers to join a practice-based research network. The APA, American Society of Addiction Medicine (ASAM), and Friends Research Institute created AMNet through a cooperative agreement with the National Institute on Drug Abuse (NIDA). AMNet, in collaboration with the American Academy of Addiction Psychiatry (AAAP), will address the opioid epidemic by helping practices and their providers drive quality improvement while creating a platform for future research. The network is focused on measuring and improving patient outcomes through the collection of data in PsychPRO - APA's CMS-Qualified Clinical Data Registry.

APA members can join PsychPRO at no cost. Non-APA members who participate in AMNet will gain complimentary access to PsychPRO through July 31st, 2022, after which there will be a nominal annual fee. AMNet members receive free CME clinical and research webinars to address the opioid epidemic.

Complete this 5-minute survey to describe your practice and check your eligibility for AMNet.

Take Survey

About AMNet

Addiction medicine and addiction psychiatry office-based practices play an important role in responding to our nation's devastating opioid epidemic. Yet, little is known about the type of patients treated in these practices, the services they receive, and their clinical outcomes. Practices often have limited opportunities to organize their patient data to inform quality improvement efforts and are rarely invited to participate in clinical research. Although much is known about opioid treatment programs (OTP) and their patients, relatively little is known about providers and the patients they treat for substance use disorders, in office-based practices, non-OTP outpatient programs, community health centers, and community mental health centers.

With funding support from the Office of the Assistant Secretary for Planning and Evaluation (ASPE) of the Department of Health and Human Services and NIDA, AMNet was created to address the nation's opioid epidemic by forging a practice-based research network.

AMNet participants will receive complimentary access to PsychPRO, APA's CMS-Qualified Clinical Data Registry for use in addiction medicine practices. PsychPRO has successfully integrated with over 15 electronic health record systems offering clinician- and patient-reported outcome measures, accessible via its clinician and patient portals, and an interactive dashboard to visualize patient-level information and facilitate data comparisons for quality improvement initiatives.

AMNet's addiction-related outcome measures in PsychPRO include:

  • Brief Addiction Monitor (BAM)
  • TAPS Tool
  • Treatment Effectiveness Assessment (TEA)
  • Short Opiate Withdrawal Scale (SOWS)
  • Clinical Opiate Withdrawal Scale (COWS)
  • Visual Analogue Scale for Opioid Craving (VAS)
  • Patient Health Questionnaire (PHQ-2)
  • PROMIS Pain Interference

In addition, psychiatric measures available in PsychPRO include:

    • DSM-5 Cross-cutting measure
    • PHQ-9
    • GAD-7

Patients can complete these tools online, prior to their visit, or in the office on tablet computers provided for free to participating clinicians. Patient responses to measures will generate graphics, visualizing treatment progress over time.

PsychPRO's Interactive Dashboard Preview:

Screenshot of the PsychPRO dashboard with the text Integrate or upload practice management data to schedule and prescribe assessments for patients to complete in their own environment or clinic setting via smartphone, tablet or laptop

Click each image below for more dashboard views:

Screenshot of the PsychPRO dashboard with the text Patients complete assessments electronically via smartphone, tablet or laptop
Screenshot of the PsychPRO dashboard with the text Clinician can engage patients in discussion about responses for treatment and care planning, and tracks summary scores over time
Screenshot of the PsychPRO dashboard with the text View quality data with a quarterly trend available by clicking the measure directly from the dashboard list

Who Should Participate in AMNet?

We are seeking practices and their providers including physicians, nurse practitioners, and physician assistants who prescribe any formulations of buprenorphine or naltrexone in a wide variety of outpatient settings, including:

  • Office-based Opioid Treatment Practices (OBOTs)
  • Intensive Outpatient Programs (IOPs)
  • Outpatient Programs (OPs)
  • Community Health Centers (CHCs, FQHCs)
  • Community Mental Health Centers (CMHCs)

Practices in health care and academic institutions, with or without EHRs, that regularly treat patients with opioid use and other substance use disorders are welcome. Practices can be located in urban, suburban, or rural areas. Telemedicine practices are eligible. We are currently not seeking providers in opioid treatment programs because more is known about their patient outcomes than in other settings.

Providers are eligible regardless of their membership status in APA, AAAP or ASAM.

Benefits of Joining AMNet

  • Free access to PsychPRO as described above
  • Real-time data to track patients' progress
  • Potential credit toward MOC Part IV Certification
  • Free CME webinars
  • $1,000 Honorarium
  • Tablet computer
  • Opportunity to participate in research
  • Support on the use of AMNet

Complete the Survey Today

If you would like to join AMNet or obtain more information, please complete the 5-minute survey using the link below.

Take Survey


Contact Us

If you have additional questions you are invited to contact us at

Contact Us

Funded by the Office of the Assistant Secretary for Planning and Evaluation of the Department of Health and Human Services and NIH/NIDA Grant Award: 3U01DA046910-02S2

The contents of this webpage are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.